Would be a great time to unveil LifeMap Solutions medical app !
October 11-12, 2014: 12th Annual Pre-Medical and Pre-Health Professions Conference, University of California, Davis
Dr. Michael West will deliver the keynote speech at the 12th Annual Pre-Medical and Pre-Health Professions Conference, “Empowering the Next Generation of Health Professionals,” on October 11-12, 2014 at University of California, Davis.
BTX next-gen breast, bladder and lung cancer tests will bring in BILLIONS.
We are now under $4, could EASILY be a double when these PanC-DX products start to be marketed in late 2014.
MENLO PARK, Calif., Sept. 4, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (ASTY) announced today that its Board of Directors has set Monday, September 15, 2014 as the record date (the "Record Date") for determining holders of its Series A common stock entitled to receive BioTime, Inc. common share purchase warrants in Asterias' previously announced warrant distribution.
Or Strong Buy
West reported yesterday bladder, lung and breast cancer testing product will be unveiled soon.
Full steam ahead
Btx first subsidiary to IPO exploded last few days if you haven't noticed. As for BTX they will likely announce release dates for their EU cancer diagnostic product.
BTX is the leader here, they have taken the risks and reaped the reward. I know no other stem cell company run with such ambition and smarts. Tomorrow BTX will update market release date of cancer diagnostic product PanC-DX.
Also BTX's subsidiary has spine regen and cancer vaccine products about to start trials.........both BILLION $ PRODUCTS.
WHO else has such an extensive pipeline?!!! It's all just starting here so get in while you can.
Again Dr. West is a genius, have other people test your product and pay for clinical studies.
Expect great things from AST & BTX. Hoping to add more shares here before spine trials actually start and we make the headlines. The Mothership is at 3.11 a share and cancer diagnostic products to be introduced in the EU by years end. Win-Win.
All animal and preclinical studies passed with flying colors. stem cell R&D products, LifeMap app, cancer diagnostics, cosmetic surgery, dendritic cancer vaccines, cartilage, tendon & bone regen, spine regen, heart and blood regen, AMD program.....even if two of these programs were to fail BTX still is probable of making BILLIONS within a few short years.
BUY & HOLD & GET RICH.
Dr. West genius coming to fruition....Hystem R&D outside of company paying off.
Belgium University hystem clinical trials to be used for vocal scarring.....Clinical trials FULLY paid for, hats off to Michael West.
BTX revs up 93%, every quarter BTX will grow exponentially thanks to LifeMaps.
“Watching the plummeting costs of sequencing the genome, and the rapid rise of other digitized medical data, we recognized that we had a good foundation [at BioTime] to build a leading service and product to manage all that data,” adds West. “Not just for researchers, but for the public in general.”
Low Profile Company, High Profile Partnership
For many observers, however, the real buzz around the soft launch of LifeMap Solutions will be its close partnership with the Icahn Institute. This is the home of Dr. Eric Schadt, who has attracted a reputation for shaking up fundamental ideas about biology and disease.
BTX is at a 5 yr low and by the end of this year will start to have products come to market. Cosmetic surgery device in the EU as well as next-gen cancer diagnostic products. Over next 3-6 months you want to be in BTX.